Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725555 | 0.87 | HPGD (0.36) | KDM4EMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL21725554 | 0.86 | PDE10A (0.38) | PDE10AKDM4EMEN1HPGDKMT2A | |
| SCHEMBL21725475 | 0.81 | TSHR (0.37) | PDE10AKDM4ENPSR1TSHR | |
| SCHEMBL21725548 | 0.81 | PDE10A (0.40) | PDE10AKDM4EMEN1HPGDKMT2A | |
| SCHEMBL21725539 | 0.79 | HPGD (0.33) | KDM4EMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL21859884 | 0.75 | HTT (0.44) | PDE10AKDM4EKMT2ANPSR1TSHR | |
| SCHEMBL21859512 | 0.75 | PDE10A (0.41) | PDE10AKDM4ENPSR1TSHR | |
| SCHEMBL21725545 | 0.74 | CRHR1 (0.37) | CRHR1TSHR | |
| SCHEMBL21725533 | 0.73 | HPGD (0.35) | KDM4EMEN1HPGDKMT2ANPSR1 | |
| SCHEMBL23015832 | 0.72 | CRHR1 (0.43) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | PDE10A 938/4885CRHR1 15/4885KDM4E 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.